MedWatch

Danish major investor clears out the board room in biotech company

NB Capital has replaced most of the members of the board in a major, Canadian biotech company after rounding up several share holders. Investors are on the lookout for any opportunity to maximize return in these days, says CEO Florian Schönharting.

Foto: PR

The Danish investment company NB Capital lead by CEO Florian Schönharting has led a direct attack on the acting board in the Canadian biotech company, QLT, by replacing six out of seven of its members, after NB Capital, which owns about 15 % of the shares, secured support from a number of the other major share holders.

The replacement came about after an intense verbal showdown with the acting board, according to stock market announcements from QLT, just as the takeover has been relayed by several international media channels.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

CHMP blåstempler ni nye lægemidler i maj

Den europæiske lægemiddelkomite, CHMP, har på dets møde i maj indstillet ni nye lægemidler til godkendelse samt anbefalet, at seks midler kan tages i brug på nye måder. To midler afvist.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier